Tenaya Therapeutics, Inc. (TNYA)
After hours:
| Previous close | 3.1900 |
| Open | 3.1800 |
| Bid | 3.1100 x 200 |
| Ask | 3.1600 x 200 |
| Day's range | 3.1200 - 3.2700 |
| 52-week range | 1.6600 - 7.0100 |
| Volume | |
| Avg. volume | 301,690 |
| Market cap | 244.975M |
| Beta (5Y monthly) | 2.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the TD Cowen Genetic Medicines & RNA Summit on Friday, June 21, 2024, at 11:20 am ET. The live presentation will be webcast and may be accessed fro
- GlobeNewswire
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with Focus on Generating Data from Clinical-Stage Gene Therapy Programs Raised $47 Million Net Proceeds in First Quarter Financing; Current Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-
- GlobeNewswire
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Abstracts Demonstrate Tenaya’s Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart MedicinesSOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present seven abstracts focused on the
